The New York Academy of Sciences
Antibody-Drug Conjugates: Oncology and Beyond
Posted March 02, 2018
Over a century ago, immunologist and founder of chemotherapy Paul Ehrlich proposed that antibodies could be what he called the “magic bullets” of cancer treatment. A key component of the immune system, antibodies identify and bind to foreign targets known as antigens. This fundamental property has informed the development of antibody–drug conjugates (ADCs), an evolving class of anticancer therapeutics that uses the selective targeting of monoclonal antibodies (mAbs) in combination with cancer-killing cytotoxic drugs. ADC research has evolved into an active, multidisciplinary field that now extends beyond uses in oncology. On November 14, 2017 the Biochemical Pharmacology Discussion Group at the New York Academy of Sciences presented Antibody–Drug Conjugates: Oncology and Beyond, a symposium on the benefits and challenges of ADCs for cancer treatment and the next wave of advancements in the field, including the use of ADCs as treatment for other disease indications.